DDInter1476 DDInter1658
Pirbuterol is a beta-2 adrenergic bronchodilator. In vitro studies and in vivo pharmacologic studies have demonstrated that pirbuterol has a preferential effect on beta-2 Adrenergic receptors compared with isoproterenol. While it is recognized that beta-2 adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that there is a population of beta-2 receptors in the human heart, existing in a concentration between 10-50%. The precise function of these receptors has not been established. The pharmacologic effects of beta adrenergic agonist drugs, including pirbuterol, are at least in proof attributable to stimulation through beta adrenergic receptors of intracellular adenyl cyclase, the enzyme which catalyzes the conversion of adenosine triphosphate (AlP) to cyclic-3†,5†-adenosine monophosphate (c-
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Pirbuterol {u} (Compound) resembles {v} (Compound) Bupranolol
Pirbuterol {u} (Compound) resembles {v} (Compound) Terbutaline
Pirbuterol {u} (Compound) treats {v} (Disease) asthma
Pirbuterol {u} (Compound) binds {v} (Gene) ADRB1
Pirbuterol {u} (Compound) is included by {v} (Pharmacologic Class) Adrenergic beta2-Agonists
Pirbuterol {u} (Compound) causes {v} (Side Effect) Dry mouth
Pirbuterol (Compound) resembles Bupranolol (Compound)
Pirbuterol (Compound) resembles Terbutaline (Compound)
Pirbuterol (Compound) treats asthma (Disease)
Pirbuterol (Compound) binds ADRB1 (Gene)
Pirbuterol (Compound) is included by Adrenergic beta2-Agonists (Pharmacologic Class)
Pirbuterol (Compound) causes Dry mouth (Side Effect)